While MS clinical trials of rituximab, ocrelizumab, and ofatumumab have shown there to be a stronger decrease in IgM levels than in IgG and IgA levels over time, short-term follow-up results have indicated that there is no association with an increased risk of infection for patients (4–6, 63, 64). Here, CD40LG is linked to infection.